Donor- and recipient-derived immunity in ABO incompatible living-related liver transplantation

Alexandra Schumann; Melanie Fiedler; Susanne Beckebaum; Vito R. Cicinnati; Kerstin Herzer; Veronika Lenz; Oliver Witzke; Andreas Paul; Michael Roggendorf; Peter A. Horn; Monika Lindemann

doi:10.1016/j.humimm.2015.09.008

Donor- and recipient-derived immunity in ABO incompatible living-related liver transplantation

Alexandra Schumann, Melanie Fiedler, Susanne Beckebaum, Vito R. Cicinnati, Kerstin Herzer, Veronika Lenz, Oliver Witzke, Andreas Paul, Michael Roggendorf, Peter A. Horn, Monika Lindemann

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

This report describes how donor- and recipient-derived immunity was influenced by immunosuppressive treatment of ABO incompatibility (rituximab and immunoadsorption/plasmaphereses) in the long-term. We present an 8-year course of Hepatitis B virus (HBV) immunity, isohemagglutinins and B cell numbers. Whereas cellular HBV immunity was transferred from the HBV vaccinated donor (blood group A1) to the HBV naïve recipient (blood group 0), humoral HBV specific immune transfer was lacking. Starting at month 17 after transplantation, the recipient was vaccinated six times against HBV. Anti-HBs did not appear until the sixth vaccination at month 44. Immunoadsorption prior to transplantation reduced anti-A1 IgG titers from 256 to 2. Titers after transplantation remained low (≤64). B cell numbers were below standard values up to month 26, then normalized and exceeded normal values from year 7 to 8 post transplantation. In conclusion, donor-derived B cell immunity was lost but recipient-derived immunity persisted after ABO incompatible transplantation.

Original language	English
Pages (from-to)	631-635
Number of pages	5
Journal	Human Immunology
Volume	76
Issue number	9
DOIs	https://doi.org/10.1016/j.humimm.2015.09.008
State	Published - Sep 2015
Externally published	Yes

Keywords

ABO incompatible transplantation
B cell numbers
Hepatitis B immunity
Isohemagglutinins
Rituximab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.humimm.2015.09.008

Cite this

@article{c1f84b09474e4419a7cd8fe686523bec,

title = "Donor- and recipient-derived immunity in ABO incompatible living-related liver transplantation",

abstract = "This report describes how donor- and recipient-derived immunity was influenced by immunosuppressive treatment of ABO incompatibility (rituximab and immunoadsorption/plasmaphereses) in the long-term. We present an 8-year course of Hepatitis B virus (HBV) immunity, isohemagglutinins and B cell numbers. Whereas cellular HBV immunity was transferred from the HBV vaccinated donor (blood group A1) to the HBV na{\"i}ve recipient (blood group 0), humoral HBV specific immune transfer was lacking. Starting at month 17 after transplantation, the recipient was vaccinated six times against HBV. Anti-HBs did not appear until the sixth vaccination at month 44. Immunoadsorption prior to transplantation reduced anti-A1 IgG titers from 256 to 2. Titers after transplantation remained low (≤64). B cell numbers were below standard values up to month 26, then normalized and exceeded normal values from year 7 to 8 post transplantation. In conclusion, donor-derived B cell immunity was lost but recipient-derived immunity persisted after ABO incompatible transplantation.",

keywords = "ABO incompatible transplantation, B cell numbers, Hepatitis B immunity, Isohemagglutinins, Rituximab",

author = "Alexandra Schumann and Melanie Fiedler and Susanne Beckebaum and Cicinnati, {Vito R.} and Kerstin Herzer and Veronika Lenz and Oliver Witzke and Andreas Paul and Michael Roggendorf and Horn, {Peter A.} and Monika Lindemann",

note = "Publisher Copyright: {\textcopyright} 2015 American Society for Histocompatibility and Immunogenetics.",

year = "2015",

month = sep,

doi = "10.1016/j.humimm.2015.09.008",

language = "English",

volume = "76",

pages = "631--635",

journal = "Human Immunology",

issn = "0198-8859",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Donor- and recipient-derived immunity in ABO incompatible living-related liver transplantation

AU - Schumann, Alexandra

AU - Fiedler, Melanie

AU - Beckebaum, Susanne

AU - Cicinnati, Vito R.

AU - Herzer, Kerstin

AU - Lenz, Veronika

AU - Witzke, Oliver

AU - Paul, Andreas

AU - Roggendorf, Michael

AU - Horn, Peter A.

AU - Lindemann, Monika

PY - 2015/9

Y1 - 2015/9

N2 - This report describes how donor- and recipient-derived immunity was influenced by immunosuppressive treatment of ABO incompatibility (rituximab and immunoadsorption/plasmaphereses) in the long-term. We present an 8-year course of Hepatitis B virus (HBV) immunity, isohemagglutinins and B cell numbers. Whereas cellular HBV immunity was transferred from the HBV vaccinated donor (blood group A1) to the HBV naïve recipient (blood group 0), humoral HBV specific immune transfer was lacking. Starting at month 17 after transplantation, the recipient was vaccinated six times against HBV. Anti-HBs did not appear until the sixth vaccination at month 44. Immunoadsorption prior to transplantation reduced anti-A1 IgG titers from 256 to 2. Titers after transplantation remained low (≤64). B cell numbers were below standard values up to month 26, then normalized and exceeded normal values from year 7 to 8 post transplantation. In conclusion, donor-derived B cell immunity was lost but recipient-derived immunity persisted after ABO incompatible transplantation.

AB - This report describes how donor- and recipient-derived immunity was influenced by immunosuppressive treatment of ABO incompatibility (rituximab and immunoadsorption/plasmaphereses) in the long-term. We present an 8-year course of Hepatitis B virus (HBV) immunity, isohemagglutinins and B cell numbers. Whereas cellular HBV immunity was transferred from the HBV vaccinated donor (blood group A1) to the HBV naïve recipient (blood group 0), humoral HBV specific immune transfer was lacking. Starting at month 17 after transplantation, the recipient was vaccinated six times against HBV. Anti-HBs did not appear until the sixth vaccination at month 44. Immunoadsorption prior to transplantation reduced anti-A1 IgG titers from 256 to 2. Titers after transplantation remained low (≤64). B cell numbers were below standard values up to month 26, then normalized and exceeded normal values from year 7 to 8 post transplantation. In conclusion, donor-derived B cell immunity was lost but recipient-derived immunity persisted after ABO incompatible transplantation.

KW - ABO incompatible transplantation

KW - B cell numbers

KW - Hepatitis B immunity

KW - Isohemagglutinins

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84944403639&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2015.09.008

DO - 10.1016/j.humimm.2015.09.008

M3 - Article

C2 - 26394233

AN - SCOPUS:84944403639

SN - 0198-8859

VL - 76

SP - 631

EP - 635

JO - Human Immunology

JF - Human Immunology

IS - 9

ER -

Donor- and recipient-derived immunity in ABO incompatible living-related liver transplantation

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this